» Articles » PMID: 37164047

Multicenter Clinical and Functional Evidence Reclassifies a Recurrent Noncanonical Filamin C Splice-altering Variant

Abstract

Background: Truncating variants in filamin C (FLNC) can cause arrhythmogenic cardiomyopathy (ACM) through haploinsufficiency. Noncanonical splice-altering variants may contribute to this phenotype.

Objective: The purpose of this study was to investigate the clinical and functional consequences of a recurrent FLNC intronic variant of uncertain significance (VUS), c.970-4A>G.

Methods: Clinical data in 9 variant heterozygotes from 4 kindreds were obtained from 5 tertiary health care centers. We used in silico predictors and functional studies with peripheral blood and patient-specific induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Isolated RNA was studied by reverse transcription polymerase chain reaction. iPSC-CMs were further characterized at baseline and after nonsense-mediated decay (NMD) inhibition, using quantitative polymerase chain reaction (qPCR), RNA-sequencing, and cellular electrophysiology. American College of Medical Genetics and Genomics (ACMG) criteria were used to adjudicate variant pathogenicity.

Results: Variant heterozygotes displayed a spectrum of disease phenotypes, spanning from mild ventricular dysfunction with palpitations to severe ventricular arrhythmias requiring device shocks or progressive cardiomyopathy requiring heart transplantation. Consistent with in silico predictors, the c.970-4A>G FLNC variant activated a cryptic splice acceptor site, introducing a 3-bp insertion containing a premature termination codon. NMD inhibition upregulated aberrantly spliced transcripts by qPCR and RNA-sequencing. Patch clamp studies revealed irregular spontaneous action potentials, increased action potential duration, and increased sodium late current in proband-derived iPSC-CMs. These findings fulfilled multiple ACMG criteria for pathogenicity.

Conclusion: Clinical, in silico, and functional evidence support the prediction that the intronic c.970-4A>G VUS disrupts splicing and drives ACM, enabling reclassification from VUS to pathogenic.

Citing Articles

ParSE-seq: a calibrated multiplexed assay to facilitate the clinical classification of putative splice-altering variants.

ONeill M, Yang T, Laudeman J, Calandranis M, Harvey M, Solus J Nat Commun. 2024; 15(1):8320.

PMID: 39333091 PMC: 11437130. DOI: 10.1038/s41467-024-52474-4.


Reduction of Filamin C Results in Altered Proteostasis, Cardiomyopathy, and Arrhythmias.

Ohiri J, Dellefave-Castillo L, Tomar G, Wilsbacher L, Choudhury L, Barefield D J Am Heart Assoc. 2024; 13(10):e030467.

PMID: 38761081 PMC: 11179814. DOI: 10.1161/JAHA.123.030467.

References
1.
Laws J, Lancaster M, Ben Shoemaker M, Stevenson W, Hung R, Wells Q . Arrhythmias as Presentation of Genetic Cardiomyopathy. Circ Res. 2022; 130(11):1698-1722. PMC: 9205615. DOI: 10.1161/CIRCRESAHA.122.319835. View

2.
Miller D, Lee K, Chung W, Gordon A, Herman G, Klein T . ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021; 23(8):1381-1390. DOI: 10.1038/s41436-021-01172-3. View

3.
Ortiz-Genga M, Cuenca S, Dal Ferro M, Zorio E, Salgado-Aranda R, Climent V . Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. J Am Coll Cardiol. 2016; 68(22):2440-2451. DOI: 10.1016/j.jacc.2016.09.927. View

4.
Holliday M, Singer E, Ross S, Lim S, Lal S, Ingles J . Transcriptome Sequencing of Patients With Hypertrophic Cardiomyopathy Reveals Novel Splice-Altering Variants in . Circ Genom Precis Med. 2021; 14(2):e003202. PMC: 8284365. DOI: 10.1161/CIRCGEN.120.003202. View

5.
Begay R, Tharp C, Martin A, Graw S, Sinagra G, Miani D . Gene Splice Mutations Cause Dilated Cardiomyopathy. JACC Basic Transl Sci. 2016; 1(5):344-359. PMC: 5166708. DOI: 10.1016/j.jacbts.2016.05.004. View